MINERALOCORTICOID ANTAGONISM: SELECTIVENESS GIVES MORE OPPORTUNITIES FOR HEART FAILURE MANAGEMENT
The review takes into consideration the novel data on heart failure treatment: application of mineralocorticoid antagonists. The pathogenetic points are highlighted that are proved by clinical trials, as epidemiological concerns. Further opportunites are sketched for this special kind of treatment b...
Main Authors: | V. N. Soboleva, E. O. Taratukhin |
---|---|
Format: | Article |
Language: | Russian |
Published: |
«FIRMA «SILICEA» LLC
2015-01-01
|
Series: | Российский кардиологический журнал |
Subjects: | |
Online Access: | https://russjcardiol.elpub.ru/jour/article/view/212 |
Similar Items
-
Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists
by: Yugar-Toledo JC, et al.
Published: (2017-10-01) -
Antihypertensive effect of the mineralocorticoid receptor antagonist eplerenone: a pooled analysis of patient-level data from comparative trials using regulatory-approved doses
by: Fernet M, et al.
Published: (2018-09-01) -
Mineralocorticoid Receptor Antagonists Eplerenone and Spironolactone Modify Adrenal Cortex Morphology and Physiology
by: Sofia S. Pereira, et al.
Published: (2021-04-01) -
THE USE OF MINERALOCORTICOID RECEPTOR ANTAGONISTS IN THE PRE VENTION OF ATRIAL FIBRILLATION
by: N. T. Vatutin, et al.
Published: (2019-07-01) -
Mineralocorticoid receptor antagonists in chronic central serous chorioretinopathy
by: Ana Sanhueza, et al.
Published: (2020-09-01)